Company Filing History:
Years Active: 2017
Title: Babette Schade: Innovator in Antitumoral Binding Molecules
Introduction
Babette Schade, an accomplished inventor based in Zurich, Switzerland, has made significant contributions in the field of biotechnology, specifically focusing on developing innovative solutions for cancer treatment. With a unique patent aimed at binding molecules with antitumoral activity, she stands at the forefront of medical advancements that may lead to more effective cancer therapies.
Latest Patents
Babette Schade holds a notable patent for her invention titled "Binding molecules with antitumoral activity." This invention involves a binding molecule that specifically targets two different epitopes of an antigen expressed on tumor cells. The binding molecule comprises a first binding (poly)peptide derived from Fyn SH3, which attaches to the first epitope, and a second binding (poly)peptide that connects to the second epitope of the antigen. Additionally, her patent includes a nucleic acid molecule that encodes this binding molecule, a vector containing this nucleic acid, and a method for producing these molecules. The invention further extends to pharmaceutical and diagnostic compositions, aiming to enhance treatment options for tumors.
Career Highlights
In her role at Covagen AG, Babette Schade has played a pivotal part in advancing research and development efforts. Her dedication to innovation is evident in the successful patent she holds, which showcases her ability to translate complex biological ideas into practical applications that may improve patient outcomes in oncology.
Collaborations
Throughout her career, Babette Schade has collaborated with esteemed colleagues such as Simon Brack and Frédéric Mourlane. These collaborations have contributed to the fruitful development of her groundbreaking patent, fostering an environment of shared expertise and innovative thinking in the field of cancer treatment.
Conclusion
Babette Schade's work is a testament to the vital role of inventors in the ongoing battle against cancer. With her patent focusing on binding molecules with antitumoral activity, she has paved the way for new approaches to treatment. As research continues to evolve, her contributions are likely to inspire further innovations that could lead to more effective therapeutic strategies for managing cancer.